LEXICON PHARMACEUTICALS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
LEXICON PHARMACEUTICALS, INC. (LXRX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.09 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.09M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.33M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.96M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.45M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $4.09M 10-K · filed 2026-03-05 |
| 2024-12-31 | $4.33M 10-K · filed 2026-03-05 |
| 2023-12-31 | $6.96M 10-K · filed 2025-03-07 |
| 2022-12-31 | $5.45M 10-K · filed 2024-03-25 |
| 2021-12-31 | $5.16M 10-K · filed 2023-03-03 |
| 2020-12-31 | $5.65M 10-K · filed 2022-03-10 |
| 2019-12-31 | $5.34M 10-K · filed 2021-03-12 |
| 2018-12-31 | $4.64M 10-K · filed 2020-03-12 |
| 2017-12-31 | $3.92M 10-K · filed 2019-03-15 |
| 2016-12-31 | $7.06M 10-K · filed 2018-03-01 |
| 2015-12-31 | $8.16M 10-K · filed 2017-03-06 |
| 2014-12-31 | $7.65M 10-K · filed 2016-03-11 |
| 2013-12-31 | $7.70M 10-K · filed 2015-03-12 |
| 2012-12-31 | $12.97M 10-K · filed 2014-03-07 |
| 2011-12-31 | $11.84M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |